Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Autoimmune Diseases
Biotech
Deerfield’s Boulevard Bio pens $1.6B deal for trispecific TCE
Boulevard Bio is paying $20 million upfront to China’s Metis TechBio for the global rights to a trispecific T-cell engager for autoimmune diseases.
James Waldron
Jun 30, 2026 8:00am
Cabaletta's autoimmune CAR-T strategy is built on 'durability'
Jun 4, 2026 8:26am
Has Novartis’ T-Charge push been overtaken by in vivo CAR-Ts?
May 22, 2026 8:28am
Odyssey CEO sees $304M IPO creating ‘little large pharma’
May 8, 2026 7:27am
Kyverna’s full SPS data set stage for first autoimmune CAR-T nod
Apr 21, 2026 6:45pm
Odyssey charts new voyage to Nasdaq after false start last year
Apr 20, 2026 7:19am
